Research programme: influenza therapy - Imperial College/Xenova

Drug Profile

Research programme: influenza therapy - Imperial College/Xenova

Alternative Names: OX40:Ig; OX40L-IgG

Latest Information Update: 01 Nov 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Imperial College of Science, Technology and Medicine; Xenova Group
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 18 Apr 2006 No development reported - Preclinical for Influenza virus infections in United Kingdom (unspecified route)
  • 24 Oct 2003 Preclinical trials in Influenza virus infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top